Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
Subscribe To Our Newsletter & Stay Updated